Research programme: recombinant human protein therapeutics - Pharming/Shanghai Institute of Pharmaceutical IndustryAlternative Names: Recombinant human Factor VIII; rhFVIII
Latest Information Update: 04 Nov 2015
At a glance
- Originator Pharming Group NV; Renova Life; Shanghai Institute of Pharmaceutical Industry
- Developer Pharming Group NV; Shanghai Institute of Pharmaceutical Industry
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Haemophilia A